Evidence map›Paper›PMID 38382162›Full record

ArticleDrug and alcohol dependence2024

Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019.

Pia M Mauro, Sarah Gutkind, Melanie S Askari, Deborah S Hasin, Hillary Samples, Christine M Mauro, Erin M Annunziato, Anne E Boustead, Silvia S Martins

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pia M MauroDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States. Electronic address: pm2838@cumc.columbia.edu.
Sarah GutkindDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States.
Melanie S AskariDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States.
Deborah S HasinDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States; New York State Psychiatric Institute, United States.
Hillary SamplesCenter for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, United States; Department of Health Behavior, Society & Policy, Rutgers University School of Public Health, United States.
Christine M MauroDepartment of Biostatistics, Columbia University Mailman School of Public Health, United States.
Erin M AnnunziatoDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States.
Anne E BousteadSchool of Government & Public Policy, University of Arizona, United States.
Silvia S MartinsDepartment of Epidemiology, Columbia University Mailman School of Public Health, United States.
Columbia University · USInstitute on Aging · USUniversity of Arizona · US

Funding

Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DEBORAH S HASIN, Silvia Saboia Martins · 2012 to 2026
$6.1M
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HASIN, DEBORAH S · 2019 to 2023
$4.1M
State medical marijuana laws and NSDUH marijuana use and consequences since 2004R01DA037866 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARTINS, SILVIA SABOIA · 2014 to 2018
$2.3M
Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatalityK01DA049950 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SAMPLES, HILLARY · 2020 to 2024
$981k
Multi-level associations between medical marijuana laws and substance use disorder treatmentK01DA045224 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURO, PIA M. · 2018 to 2022
$878k
The Role of Financial Strain in Adult Alcohol, Cannabis, CNS Depressant and Polysubstance Use, and Mitigating Effects of Earned Income Tax Credit Policies: a Longitudinal Study using PATH dataR36DA058180 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GUTKIND, SARAH · 2023 to 2024
$64k
NIDA NIH HHS K01 DA045224NIDA NIH HHS K01 DA049950NIDA NIH HHS R01 DA037866NIDA NIH HHS R01 DA048860NIDA NIH HHS R36 DA058180NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

backgroundCannabis use disorder (CUD) treatment prevalence decreased in the US between 2002 and 2019, yet structural mechanisms for this decrease are poorly understood. We tested associations between cannabis laws becoming effective and self-reported CUD treatment.

methodsRestricted-use 2004-2019 National Surveys on Drug Use and Health included people ages 12+ classified as needing CUD treatment (i.e., past-year DSM-5-proxy CUD or last/current specialty treatment for cannabis). Time-varying indicators of medical cannabis laws (MCL) with/without cannabis dispensary provisions differentiated state-years before/after laws using effective dates. Multi-level logistic regressions with random state intercepts estimated individual- and state-adjusted CUD treatment odds by MCLs and model-based changes in specialty CUD treatment state-level prevalence. Secondary analyses tested associations between CUD treatment and MCL or recreational cannabis laws (RCL).

resultsUsing a broad treatment need sample definition in 2004-2014, specialty CUD treatment prevalence decreased by 1.35 (95 % CI = -2.51, -0.18) points after MCL without dispensaries and by 2.15 points (95 % CI = -3.29, -1.00) after MCL with dispensaries provisions became effective, compared to before MCL. Among people with CUD in 2004-2014, specialty treatment decreased only in MCL states with dispensary provisions (aPD = -0.91, 95 % CI = -1.68, -0.13). MCL were not associated with CUD treatment use in 2015-2019. RCL were associated with lower CUD treatment among people classified as needing CUD treatment, but not among people with past-year CUD.

conclusionsPolicy-related reductions in specialty CUD treatment were concentrated in states with cannabis dispensary provisions in 2004-2014, but not 2015-2019, and partly driven by reductions among people without past-year CUD. Other mechanisms (e.g., CUD symptom identification, criminal-legal referrals) could contribute to decreasing treatment trends.

Indexed as

CannabisHallucinogensMarijuana AbuseMedical MarijuanaSubstance-Related DisordersAdultHumansPolicyUnited StatesHallucinogensMedical MarijuanaCannabisCannabis policyMedical cannabis lawPolicyRecreational cannabis lawTreatment

Identifiers

PMID38382162
PMCPMC11736659
OpenAlexW4391469561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.